Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. We show 43 historical shares outstanding datapoints in our LPCN shares outstanding history coverage, used to compute LPCN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LPCN market cap history over the course of time is important for investors
interested in comparing LPCN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LPCN versus a peer is one thing; comparing
LPCN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LPCN can fluctuate over the course of history.
With this page we aim to empower investors researching LPCN by allowing them to research the LPCN market cap history. |
Free LPCN Email Alerts:
Video: The Importance of Market Cap
